GENE - CHEMICAL INTERACTIONS REPORT
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
Object Symbol | Qualifier | Evidence | With | Reference | Source | Notes | Original Reference(s) | Bcl2l1 | multiple interactions | EXP | | 6480464 | CTD | pyrazolanthrone inhibits the reaction [Acetaminophen results in increased expression of BCL2L1 protein modified form] | PMID:20166895 | Bcl2l1 | multiple interactions | ISO | BCL2L1 (Homo sapiens) | 6480464 | CTD | [pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; [XMU-MP-1 co-treated with pyrazolanthrone co-treated with U 0126] inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [[Sulindac co-treated with Arsenic Trioxide] results in increased phosphorylation of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [fisetin results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [naphtho(1,2-b)furan-4,5-dione results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [nickel sulfate results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [pachastrissamine analog inhibits the reaction [BCL2L1 protein binds to BECN1 protein]] | PMID:18281123 PMID:19540902 PMID:19747539 PMID:31044527 PMID:35123989 PMID:35499276 | |
Go Back to source page | Continue to Ontology report |